Arthur He
Stock Analyst at HC Wainwright & Co.
(4.51)
# 270
Out of 5,241 analysts
53
Total ratings
57.89%
Success rate
34.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arthur He
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JBIO Jade Biosciences | Maintains: Buy | $35 → $45 | $22.00 | +104.55% | 3 | Apr 27, 2026 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $165 → $185 | $67.20 | +175.30% | 7 | Apr 20, 2026 | |
| SLDB Solid Biosciences | Reiterates: Buy | $20 | $6.59 | +203.49% | 11 | Mar 23, 2026 | |
| VERA Vera Therapeutics | Maintains: Buy | $90 → $110 | $34.00 | +223.53% | 4 | Mar 2, 2026 | |
| ADAG Adagene | Maintains: Buy | $8 → $7 | $3.37 | +108.02% | 11 | Aug 15, 2025 | |
| AUPH Aurinia Pharmaceuticals | Assumes: Buy | $17 | $15.57 | +9.22% | 1 | Jul 30, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $2.79 | - | 8 | May 20, 2025 | |
| BCAB BioAtla | Reiterates: Neutral | n/a | $4.04 | - | 8 | Mar 31, 2025 |
Jade Biosciences
Apr 27, 2026
Maintains: Buy
Price Target: $35 → $45
Current: $22.00
Upside: +104.55%
Nektar Therapeutics
Apr 20, 2026
Maintains: Buy
Price Target: $165 → $185
Current: $67.20
Upside: +175.30%
Solid Biosciences
Mar 23, 2026
Reiterates: Buy
Price Target: $20
Current: $6.59
Upside: +203.49%
Vera Therapeutics
Mar 2, 2026
Maintains: Buy
Price Target: $90 → $110
Current: $34.00
Upside: +223.53%
Adagene
Aug 15, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.37
Upside: +108.02%
Aurinia Pharmaceuticals
Jul 30, 2025
Assumes: Buy
Price Target: $17
Current: $15.57
Upside: +9.22%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.79
Upside: -
BioAtla
Mar 31, 2025
Reiterates: Neutral
Price Target: n/a
Current: $4.04
Upside: -